![Gavin B Samuels](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Gavin B Samuels
Direktor/Vorstandsmitglied bei Dynamix Pharmaceuticals Ltd.
Aktive Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Oren M. Becker | M | - |
Dynamix Pharmaceuticals Ltd.
![]() Dynamix Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Dynamix Pharmaceuticals Ltd. discovers and develops small-molecule drugs for treating cancer and autoimmune disorders. It focuses its discovery on cancer metabolism modulators and type II selective kinase inhibitors. The firm offers DNX-03000 that targets Pyruvate Kinase M2 (PKM2), an enzyme that is a key mediator of cancer metabolism; and DNX-06000 that targets an undisclosed target. The company was founded by Oren M. Becker in 2009 and is headquartered in Rehovot, Israel. | - |
Morris Laster | M | 60 |
Dynamix Pharmaceuticals Ltd.
![]() Dynamix Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Dynamix Pharmaceuticals Ltd. discovers and develops small-molecule drugs for treating cancer and autoimmune disorders. It focuses its discovery on cancer metabolism modulators and type II selective kinase inhibitors. The firm offers DNX-03000 that targets Pyruvate Kinase M2 (PKM2), an enzyme that is a key mediator of cancer metabolism; and DNX-06000 that targets an undisclosed target. The company was founded by Oren M. Becker in 2009 and is headquartered in Rehovot, Israel. | - |
Batsheva Elran | F | 65 |
Dynamix Pharmaceuticals Ltd.
![]() Dynamix Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Dynamix Pharmaceuticals Ltd. discovers and develops small-molecule drugs for treating cancer and autoimmune disorders. It focuses its discovery on cancer metabolism modulators and type II selective kinase inhibitors. The firm offers DNX-03000 that targets Pyruvate Kinase M2 (PKM2), an enzyme that is a key mediator of cancer metabolism; and DNX-06000 that targets an undisclosed target. The company was founded by Oren M. Becker in 2009 and is headquartered in Rehovot, Israel. | - |
Ofer Shpilberg | M | - |
Dynamix Pharmaceuticals Ltd.
![]() Dynamix Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Dynamix Pharmaceuticals Ltd. discovers and develops small-molecule drugs for treating cancer and autoimmune disorders. It focuses its discovery on cancer metabolism modulators and type II selective kinase inhibitors. The firm offers DNX-03000 that targets Pyruvate Kinase M2 (PKM2), an enzyme that is a key mediator of cancer metabolism; and DNX-06000 that targets an undisclosed target. The company was founded by Oren M. Becker in 2009 and is headquartered in Rehovot, Israel. | - |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Statistik
Land | Beziehungen | % des Gesamten |
---|---|---|
Israel | 4 | 100,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Gavin B Samuels
- Persönliches Netzwerk